Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis?

REFERENCES

• Anon. (1993). Report of the Expert Committee on Kala-azar in Bihar. New Delhi: Director General of Health Services, Ministry of Health and Family Welfare.
   Google Scholar
• Berman, J. D. & Wyler, D. J. (1980). An in vitro model for investigation of chemotherapeutic agents in Leishmania. Journal of Infectious Diseases, 142, 83–86.
   PubMed Web of Science ®Google Scholar
• Bindschadler, D. & Bennett, J. (1969). A pharmacologic guide to the clinical use of amphotericin B. Journal of Infectious Diseases, 120, 427–436.
   PubMed Web of Science ®Google Scholar
• Bolard, J. (1986). How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochimica et Biophysica Acta, 864, 257–304.
   PubMed Web of Science ®Google Scholar
• Butler, W., Bennett, J., Alling, D., Wertlake, P., Utz, J. & Hill, G. (1964). Nephrotoxicity of amphotericin B. Early and late effects of 81 patients. Annals of Internal Medicine, 61, 175–187.
   PubMed Web of Science ®Google Scholar
• Chavanet, P. Y., Garry, I., Charlier, N., Caillot, D., Jean Paul, K., D'Athis, M. & Portier, H. (1992). Trial of glucose versus fat emulsion in preparation of amphotericin B for use in HIV infected patients with candidiasis. British Medical Journal, 305, 921–925.
   PubMed Web of Science ®Google Scholar
• Chia, J. & McManus, E. (1990). In vitro tumour necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrobial Agents and Chemotherapy, 34, 906–908.
   PubMed Web of Science ®Google Scholar
• De Monaco, J. & McGovern, B. (1983). Transient asystole associated with amphotericin B infusion. Drug Intelligence and Clinical Pharmacology, 17, 547–549.
   PubMedGoogle Scholar
• Dick, J. D., Rosengard, B. R., Merr, W. G., Stuart, R. K., Hutchins, G. M. & Saral, R. (1985). Fatal disseminated candidiasis due to amphotericin B resistant Candida guilliermondi. Annals of Internal Medicine, 102, 68–69.
   PubMed Web of Science ®Google Scholar
• Gallis, H., Drew, R. & Pickard, W. (1990). Amphotericin B: 30 years of clinical experience. Reviews of Infectious Diseases, 12, 308–328.
   PubMedGoogle Scholar
• Gigliotti, F., Shenep, J., Lott, L. & Thornton, D. (1987). Induction of prostagland synthesis as the mechanism responsible for chills and fever produced by infusion of amphotericin. Journal of Infectious Diseases, 156, 784–789.
   PubMed Web of Science ®Google Scholar
• Hebeka, E. K. & Salotorovsky, M. (1965). Development of resistance to polyene antibiotics in Candida albicans. Journal of Bacteriology, 89, 1533–1539.
   PubMed Web of Science ®Google Scholar
• Medoff, G. & Kobayashi, G. (1980). Strategies in the treatment of systemic fungal infections. New England Journal of Medicine, 302, 145–155.
   PubMed Web of Science ®Google Scholar
• Merz, W. G. & Sandford, G. R. (1979). Isolation and characterisation of polyene-resistant variant of Candida tropicalis. Journal of Clinical Microbiology, 9, 677–680.
   PubMed Web of Science ®Google Scholar
• Pappagianis, D., Collins, M. S., Hector, R. & Remington, J. (1979). Development of resistance to amphotericin B in Candida insistanise infecting a human. Antimicrobial Agents and Chemotherapy, 16, 123–126.
   PubMed Web of Science ®Google Scholar
• Thakur, C. P. (1993). Diminishing effectiveness of commonly used drug in treatment of kala-azar and amphotericin B in antimony and pentamidine resistant kala-azar. In Current Trends in Leishmania Research, eds Bhaduri, A. N., Basu, M. K., Sen, A. K. & Kumar, S. pp. 234–262. New Delhi: Council of Scientific and Industrial Research.
   Google Scholar
• Thakur, C. P., Sinha, G. P., Barat, D. & Pandey, A. K. (1994a). Daily versus alternate day regimen of amphotericin B in the treatment of kala-azar. Bulletin of the World Health Organization, in press.
   Google Scholar
• Thakur, C. P., Sinha, G. P., Barat, D. & Singh, R. K. (1994b). Two-hour versus 6-hour administration of amphotericin B in the treatment of kala-azar. International Journal of Antimicrobial Agents, in press.
   Google Scholar
• Thakur, C. P., Sinha, G. P., Pandey, A. K., Barat, D. & Sinha, P. K. (1993a). Amphotericin B in resistant kala-azar in Bihar. National Medical Journal of India, 6, 57–60.
   PubMedGoogle Scholar
• Thakur, C. P., Sinha, G. P., Sharma, V., Pandey, A. K., Kumar, M. & Verma, B. B. (1993b). Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian Journal of Medical Research, 97, 170–175.
   PubMed Web of Science ®Google Scholar
• Thakur, C. P., Sinha, G. P., Sharma, V., Pandey, A. K., Sinha, P. K. & Bara, D. (1993c). Efficacy of amphotericin B in multidrug resistant kala-azar in children in first decade of life. Indian Journal of Paediatrics, 60, 29–36.
   PubMedGoogle Scholar
• Tolins, J. P. & Leopoldo, R. (1988). Adverse effect of amphotericin B administration on renal hemodynamics in the rat. Neurohumoral mechanism and influence of calcium channel blockade. Journal of Pharmacology and Experimental Therapeutics, 245, 594–595.
   PubMed Web of Science ®Google Scholar
• Utz, J., Bennett, J., Brandiss, M., Butler, W. & Hill, G. (1964). Amphotericin B toxicity. Annals of Internal Medicine, 61, 334–54.
   Web of Science ®Google Scholar
• Warnock, D. (1991). Amphotericin B: an introduction. Journal of Antimicrobial Chemotherapy, 28 (Suppl. B), 27–38.
   PubMed Web of Science ®Google Scholar
• Wasan, K. M., Vadiel, K., Lopez Berestein, G., Verani, R. R. & Luke, D. R. (1990). Pentoxifyllin in amphotericin B toxicity: rat model. Antimicrobial Agents and Chemotherapy, 24, 241–244.
   Web of Science ®Google Scholar
• Winston, D. J., Gale, R. P., Meyer, D. V. & Young, L. S. (1979). Infectious complications of human bonemarrow transplantation. Medicine (Baltimore), 58, 1–3.
   Google Scholar
• World Health Organization (1982). Report of the Informal Meeting on the Chemotherapy of Visceral Leishmaniasis. Document TDR/Chem Leish/VL 82.3. Geneva: WHO.
   Google Scholar
• World Health Organization (1984). The Leishmaniases. Technical Report Series No. 701. Geneva: WHO.
   Google Scholar
• World Health Organization (1990a). Drugs used in Parasitic Diseases. Geneva: WHO.
   Google Scholar
• World Health Organization (1990b). Control of the Leishmaniasis. Technical Report Series No. 793. Geneva: WHO.
   Google Scholar